Case/noncase analysis of the FDA Adverse Events Reporting System suggests higher reporting odds of photosensitivity and esophageal symptoms for sarecycline than of those for other tetracyclines.

HOME
>
論文・技術情報
>
Case/noncase analysis of the FDA Adverse Events Reporting System suggests higher reporting odds of photosensitivity and esophageal symptoms for sarecycline than of those for other tetracyclines.

アブストラクト
ジャーナル名	Journal of the American Academy of Dermatology
Pubmed追加日	2022/2/23
投稿者	Jedlowski, Patrick M; Jedlowski, Mahdieh F
組織名	Division of Dermatology, University of Arizona College of Medicine-Tucson,;Arizona. Electronic address: pjedlowski@email.arizona.edu.;Arizona.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/35192901/